Related Experiment Video
Updated: Jul 19, 2025
Author Spotlight: Advancing Rapid Detection of Respiratory Pathogens Using Microfluidic Chip
Published on: March 29, 2024
Implementation of a Rapid Multiplex Polymerase Chain Reaction Pneumonia Panel and Subsequent Antibiotic De-escalation
Molly M Miller1, Trevor C Van Schooneveld2, Erica J Stohs2
1Department of Pharmaceutical and Nutrition Care, Nebraska Medicine, Omaha, Nebraska, USA.
Background:
Net effects of implementation of a multiplex polymerase chain reaction (PCR) pneumonia panel (PNP) on antimicrobial stewardship are thus far unknown. This retrospective study evaluated the real-world impact of the PNP on time to antibiotic de-escalation in critically ill patients treated for pneumonia at an academic medical center.
Methods:
This retrospective, quasi-experimental study included adult intensive care unit (ICU) patients with respiratory culture results from 1 May to 15 August 2019 (pre-PNP group) and adult ICU patients with PNP results from 1 May to 15 August 2020 (PNP group) at Nebraska Medical Center. Patients were excluded for the following reasons: any preceding positive coronavirus disease 2019 PCR test, lack of antibiotic receipt, or non-respiratory tract infection indications for antibiotics. The primary outcome was time to discontinuation of anti-methicillin-resistant Staphylococcus aureus (MRSA) therapy. Secondary outcomes included time to discontinuation of antipseudomonal therapy, frequency of early discontinuation for atypical coverage, and overall duration (in days) of antibiotic therapy for pneumonia.
Results:
Sixty-six patients in the pre-PNP group and 58 in the PNP group were included. There were significant differences in patient characteristics between groups. The median time to anti-MRSA agent discontinuation was 49.1 hours in the pre-PNP and 41.8 hours in the PNP group (P = .28). The median time to discontinuation of antipseudomonal agents was 134.4 hours in the pre-PNP versus 98.1 hours in the PNP group (P = .47). Other outcomes were numerically but not significantly improved in our sample.
Conclusions:
This early look at implementation of a multiplex PNP did not demonstrate a statistically significant difference in antibiotic use but lays the groundwork to further evaluate a significant real-world impact on antibiotic de-escalation in ICU patients treated for pneumonia.
Insights
The multiplex polymerase chain reaction (PCR) pneumonia panel (PNP) did not significantly shorten antibiotic de-escalation times in critically ill patients. Further research is needed to evaluate its real-world impact on antimicrobial stewardship.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Clinical Microbiology
Background:
- Antimicrobial stewardship aims to optimize antibiotic use and combat resistance.
- The impact of multiplex polymerase chain reaction (PCR) pneumonia panels (PNP) on antimicrobial stewardship is not well understood.
- Evaluating the real-world effectiveness of new diagnostic tools is crucial for improving patient care.
Purpose of the Study:
- To assess the impact of implementing a multiplex PNP on antibiotic de-escalation in critically ill pneumonia patients.
- To determine if PNP use influences the time to discontinue specific antibiotic therapies, such as anti-MRSA and antipseudomonal agents.
- To explore secondary outcomes related to early discontinuation of atypical coverage and overall antibiotic duration.
Main Methods:
- Retrospective, quasi-experimental study comparing patients before and after PNP implementation.
- Inclusion of adult ICU patients with respiratory culture or PNP results.
- Exclusion criteria included prior COVID-19, lack of antibiotics, or non-respiratory infections.
Main Results:
- No statistically significant difference in time to discontinue anti-MRSA therapy (49.1 vs. 41.8 hours; P=.28).
- No statistically significant difference in time to discontinue antipseudomonal therapy (134.4 vs. 98.1 hours; P=.47).
- Numerically improved secondary outcomes were not statistically significant in this cohort.
Conclusions:
- Early implementation of multiplex PNP did not demonstrate a statistically significant impact on antibiotic de-escalation in this study.
- The findings suggest a need for further investigation into the real-world clinical and antimicrobial stewardship benefits of PNP.
- This study provides a foundation for future research on optimizing diagnostic strategies in pneumonia management.
Related Concept Videos
01:30Pneumonia III: Complications and Assessment
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...